|Bid||36.82 x 800|
|Ask||37.02 x 1400|
|Day's Range||35.57 - 37.37|
|52 Week Range||18.55 - 42.99|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 14) GENMAB A/S/S ADR (NASDAQ: GMAB ) (announced first-half ...
Deciphera Pharmaceuticals continued a two-day sprint Wednesday on excitement over a stomach cancer treatment, but at least one analyst far prefers rival biotech company Blueprint Medicines.
Deciphera's (DCPH) pipeline candidate, ripretinib, improves progression free survival in a pivotal study evaluating it in previously treated, advanced gastrointestinal stromal tumors.
Investors love biotech stocks for the lottery ticket-like returns they can offer if a company strikes medical gold. Case in point: Deciphera Pharmaceuticals (DCPH), whose shares skyrocketed nearly 80% today.The cause of all the enthusiastic commotion? Deciphera announced positive top-line results from its pivotal Phase III study of ripretinib for the treatment of fourth-line and fourth-line plus gastrointestinal stromal tumor (GIST) patients. Specifically, ripretinib has demonstrated an impressive mPFS improvement of 6.3 months which far exceeded investor expectations of ~4 months.The million-dollar question is whether Deciphera stock can keep up this strong rally. For Deutsche Bank analyst Konstantinos Aprilaki the answer is quite clear — the analyst sees this stock as a flower that keeps blossoming.Despite the appreciation in shares, Aprilaki reiterates a Buy rating on DCPH, while boosting his price target to $62 (from $42). For perspective, Deciphera’s stock closed at $35.90 today, so this implies upside of more than 70%. (To watch Aprilaki's track record, click here) Aprilaki commented, "We believe this result, coupled with the relatively clean safety profile exhibited across ripretinib clinical trials, largely de-risk the company’s planned NDA submission to the FDA in 1Q20 in the setting of advanced GIST, and thereby increase our POS in this setting from 90% to 95%. Further, we emphasize that we see positive read through to the ongoing pivotal Phase III study of ripretinib in 2L GIST (INTRIGUE), given that the active comparator in that trial, sunitinib, is associated with a mPFS of only 5.5 months; we increase our POS in this setting from 65% to 75%." "We also adjust our estimates for predicted peak duration of treatment in both 4L and 2L GIST to reflect not only the mPFS result for INVICTUS but what we see as an increased likelihood for treatment post progression given the mOS of 15.1 months reported; 8 months and 11 months, respectively. Lastly, we increase the assumed price for ripretinib in our model from $27,500/month to $30,000/month to better reflect the value proposition we see for the asset," the analyst added.Aprilaki is certainly not the first analyst with an optimistic outlook for this drug maker, as TipRanks analytics showcasing Deciphera stock as a Strong Buy. With an average price target of $44.80, analysts are predicting an upside of nearly 25%. In total, the stock has received 6 back-to-back 'buy' ratings in the last three months. (See DCPH's price targets and analyst ratings on TipRanks)
Deciphera Pharmaceuticals stock nearly doubled Tuesday after the biotech company said its stomach cancer treatment benefited patients who've exhausted at least three other options.
Deciphera Pharma stock more than doubled on positive results from a Phase III clinical study of its drug to treat patients with advanced gastrointestinal stromal tumors.
The treatment, ripretinib, was tested against placebo in 129 patients with advanced gastrointestinal stromal tumors (GIST), a rare cancer affecting the digestive tract, who had received at least 3 prior therapies. Ripretinib demonstrated a median progression-free survival rate of 6.3 months compared with a month in case of placebo, the company said, adding that the drug significantly reduced the risk of disease progression or death by 85%. According to the American Cancer Society, more than 11,000 Americans will die from stomach cancer in 2019.
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Arcadia Biosciences (NASDAQ: RKDA ) shares ...
After sixteen years of work, Waltham drugmaker Deciphera Pharmaceuticals Inc. is set to ask the FDA for permission to bring its first product to market next year.
Shares of Deciphera Pharmaceuticals Inc. more than doubled toward a 14-month high in active premarket trading Tuesday, after the biopharmaceutical company said a phase 3 trial of its treatment of gastrointestinal stromal tumors (GIST) achieved its primary endpoint, paving the way for the company to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration. The stock rocketed 125% on volume of over 1.1 million shares ahead of the open, compared with the full-day average volume of about 293,000 shares. The primary endpoint of the study was improved progression free survival (PFS). A key secondary endpoint of objective response rate (ORR) was not statistically significant. The stock has lost 5.0% year to date through Monday, while the iShares Nasdaq Biotechnology ETF has gained 8.0% and the S&P 500 has climbed 15.0%.
Deciphera Pharmaceuticals Inc's shares more than doubled on Tuesday after the drugmaker said its treatment helped stomach cancer patients live longer without their disease worsening in a late-stage study. The treatment, ripretinib, was tested against placebo in 129 patients with advanced gastrointestinal stromal tumors (GIST), a rare cancer affecting the digestive tract, who had received at least 3 prior therapies. Ripretinib demonstrated a median progression-free survival rate of 6.3 months compared with a month in case of placebo, the company said, adding that the drug significantly reduced the risk of disease progression or death by 85%.
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the first quarter. One of these stocks was Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH). Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) shareholders have […]
Deciphera Pharmaceuticals (DCPH) needs investors to pay close attention to the stock based on moves in the options market lately.
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. But if you buy individual stocks, you can do both better or worse than that. Unfortunately the Deciphera Pharmaceut...
The Massachusetts biotech industry's executive shake-up continues, with Deciphera Pharmaceuticals' CEO Mike Taylor stepping down from the company as it approaches its first commercial product.
Shares of all three cancer-focused companies shot higher after one of their peers got bought out for a sizable premium.
Raymond James launched coverage of two pharmaceutical names Tuesday afternoon with bullish ratings. Raymond James' Laura Chico initiated coverage of Deciphera Pharmaceuticals with an Outperform rating and $47 price target.